Jabil’s (NYSE:JBL) Jabil Healthcare division announced today that it launched its Qfinity auto-injector platform.
St. Petersburg, Florida-based Jabil Healthcare designed the reusable Qfinity platform for simple subcutaneous drug self-administration at a lower cost than market alternatives.
According to a news release, the Qfinity platform supports “the emerging prioritization” of sustainable drug delivery within the pharmaceutical industry. The company said it helps patients self-administer a variety of injectables, including larger-volume, higher-viscosity medicines.
Qfinity handles over 100 injections per device and accommodates 1 mL or 2.25 mL pre-filled, disposable cassettes. Jabil estimates that the autoinjector delivers up to a 65% reduction in cost per injection compared to the market-leading disposable autoinjector, plus up to a 60% reduction in carbon footprint per injection, 50% manufacturing footprint and a 70% reduction in capital expenditure.
The launch means Jabil Healthcare’s pharmaceutical delivery systems arm will directly offer a drug delivery device platform for the first time.
“The Qfinity autoinjector platform is versatile with broad technical specifications for drug volumes and drug viscosities. It features a patient-centric form factor at up to 65% lower cost per injection than market-leading disposable autoinjectors,” Jabil Healthcare Business Unit Director Oliver Eden said in the release. “Our product is intentionally designed to be sustainable and reusable at the core, all while being delivered at a lower cost than market alternatives.”
Jabil said it also made the handheld device available in a connected version, called the Qfinity+ autoinjector, enabling medical teams to remotely monitor patients’ care and compliance through built-in sensors and electronics. Data is captured and transmitted through the Qfinity+ Home Hub solution, which offers charging and cellular data transfer functionality in near-real time without needing patient input.
“Qfinity+ enables connectivity without impacting ease of use, while enabling seamless data transfer at up to 20% lower cost per injection compared to unconnected, market-leading disposable autoinjectors,” Jabil Senior Director of Strategic Projects Conor Mulcahy said. “Within the disposable mechanical autoinjector market, a common route for delivering connectivity is a ‘sleeve’ that fits over the autoinjector and captures adherence and/or compliance and communicates those events to the user’s smartphone via Bluetooth. Jabil’s decision to instead develop the cellular Qfinity+ Home Hub solution goes back to our primary objective: maximizing access.”
